martes, 4 de febrero de 2020

European regulators could take a harder line on Agios' blood cancer drug

European regulators could take a harder line on Agios' blood cancer drug

Cancer Briefing

STAT Plus: European regulators could take a harder line on the review of an Agios blood cancer drug

By ADAM FEUERSTEIN


RUBY WALLAU FOR STAT
A European regulatory setback for a Bristol-Myers Squibb blood-cancer drug could have a negative spillover effect for Agios Pharmaceuticals.

No hay comentarios: